Stock Market

Peruse the cesspool of the Internet long enough and you’ll come across admonitions to ignore Wall Street upgrades or more simply, stocks that analysts love. These fools and charlatans don’t know what they’re talking about, keyboard commandos proclaim. While analysts are humans and are subject to errors, they can be incredibly valuable, too. First, they
Despite their potentially high growth potential, there are also a handful of quality lithium stocks that pay dividends. Buying these companies may be an effective way for some investors to maximize their total return, via share price appreciation as well as annual dividends. It’s clear that the clean energy transformation has just gotten started. Governments
Insider stock purchases are notable because they signal confidence in the company. So, investors should pay attention if an executive at Intel (NASDAQ:INTC) made a large-scale share purchase. This, along with Intel’s ambitious sales outlook, are reasons to consider INTC stock now. As we’ll see, Intel’s most recently released quarterly results weren’t perfect. There are notable
Recent industry and macro factors caused Nvidia (NASDAQ:NVDA) stock to dip, sparking concerns about its 2023 rally. Despite a slight decline, don’t dismiss the ongoing generative AI mega trend driving its powerful performance.  That said, investors should recognize the limits of Nvidia’s growth potential despite the market’s enthusiasm for AI. While NVDA benefits from AI
In 2014, Massachusetts-based T2 Biosystems (NASDAQ:TTOO) went public at $11 per share. Expectations were high for the young startup. Its sepsis-detecting products targeted a $20.3 billion industry, and T2’s Magnetic Resonance Platform (T2MR) was potentially game-changing. Shares would quickly rise to a pre-split $23. The product, however, would prove a dud. In 2020, most of
Investors should expect a steep selloff among artificial intelligence stocks, as Wall Street cashes in on the high valuations many companies in this sector provide. On the other hand, some high-potential AI names remain overlooked, and the recent AI craze has done little to uplift their valuation. Thus, as the rally cools, smart investors will
The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist (VC) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups. These startups have advanced medicine overall, improving cell therapy, tissue regeneration, genetic medicine, and more. With increasing innovation, we see
Last week, meme investors “discovered” Rite Aid (NYSE:RAD), sending its shares up 70%. The Wall Street Journal would quickly give the company a meme stock crown. For most traditional investors, Rite Aid looks like a terrible bet. The struggling drug retailer hasn’t been profitable since 2017, and a deal five years ago to sell 1,932